Amoy Diagnostics
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
Alercell to Distribute Amoy Diagnostic Ros1 Gene Fusion Detection Kit in US
The 14-fusion PCR assay for lung cancer subtyping is available for research-use only but will be more broadly distributed when the kits gain FDA clearance.
In Brief This Week: Labcorp, QuantuMDx, LumiraDx, Danaher, Thermo Fisher Scientific, and More
News items for the in vitro diagnostics industry for the week of Feb. 21, 2022.
Amoy Diagnostics, Pierre Fabre Collaborate to Develop CDx in China
The companion diagnostic kits will support marketing authorization applications for Pfizer's Braftovi and Mektovi.
Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan
Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.
Nov 25, 2019
AmoyDx, Eisai Form CDx Development Alliance
Oct 12, 2018
AmoyDx Lung Cancer CDx Approved in South Korea
Jan 29, 2018
AmoyDx, Medikonia Ink MDx Distribution Deal
May 16, 2017